From the Department of Neuroscience, Research Center in Neuroscience and Neuropsychology, Palermo University, Buenos Aires, Argentina (Drs. Vázquez and Lolich); Department of Psychiatry, Queens University, Kingston, Ontario, Canada (Dr. Vázquez); International Consortium for Psychotic & Mood Disorders Research, McLean Hospital, Belmont, MA (Drs. Vázquez, Tondo, and Baldessarini); Department of Psychiatry & Psychotherapy, Kútvölgyi Clinical Center, Semmelweis University, Budapest, Hungary (Dr. Gonda); MTA-SE Neuropsychopharmacology Research Group, Hungarian Academy of Sciences & Semmelweis University, Budapest (Dr. Gonda); Laboratory for Suicide Prevention and Research, National Institute for Psychiatry & Addictology, Budapest (Dr. Gonda); National Council of Scientific & Technical Research (CONICET), Argentina (Dr. Lolich); Department of Psychiatry, Harvard Medical School (Drs. Tondo and Baldessarini); Lucio Bini Mood Disorders Centers, Cagliari & Rome, Italy (Dr. Tondo).
Original manuscript received 26 August 2016; revised manuscript received 12 December 2016, accepted for publication 20 January 2017.
Supported by a Janos Bolyai Research Fellowship from the Hungarian Academy of Science (Dr. Gonda) and grants from the Aretæus Foundation of Rome (Dr. Tondo) and from the Bruce J. Anderson Foundation and McLean Private Donors Research Fund (Dr. Baldessarini).
Correspondence: Dr. Gustavo Vázquez, Department of Psychiatry, Queens University, Kingston, Ontario, Canada. Email: [email protected]
Supplemental digital contents are available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s Web site (www.harvardreviewofpsychiatry.org).
